Tumor-induced Osteomalacia: a Case Report

Overview

Journal J Med Case Rep

Publisher Biomed Central

Specialty General Medicine

Date 2022 Jan 12

PMID 35016725

Authors

Khalid Aligail

Joel A Dave

Ian Louis Ross

Affiliations

Soon will be listed here.

Abstract

Background: Tumor-induced osteomalacia is a rare, acquired paraneoplastic syndrome, including hypophosphatemia, high serum alkaline phosphatase, reduced active vitamin D, suboptimal bone mineral density, bone pain, fragility fractures, and muscle weakness.

Case Presentation: We report a case of 74-year-old male of mixed ancestry with hypophosphatemia resistant to treatment despite optimal compliance, associated with profound reduction of bone mineral density and multiple nontraumatic fractures, including bilateral rib fractures, lower-thoracic (T11, T12) vertebrae, and two fractures involving the surgical and anatomical neck of the right humerus. We discuss an approach to identifying the underlying cause of hypophosphatemia associated with fragility fractures, and options for management of this rare condition.

Conclusion: Although rare, tumor-induced osteomalacia can be diagnosed if a logical stepwise approach is implemented. Surgery could be curative if the tumor is properly located and is resectable.

Citing Articles

A case report of Tumor-Induced Osteomalacia (TIO) caused by central giant cell granuloma.

Rad S, Bahrami A, Houshyar J, Farrin N, Najafipour F, Amirazad H Bone Rep. 2024; 22:101804.

PMID: 39314547 PMC: 11417589. DOI: 10.1016/j.bonr.2024.101804.

Atraumatic Fractures in Multi-Morbid Older Adults: A Series of Five Cases and Review of Literature.

Rohaiem S, Khan B, Al-Julaih G, Mohammedin A Cureus. 2024; 15(12):e51333.

PMID: 38288221 PMC: 10824280. DOI: 10.7759/cureus.51333.

References

Jung G, Kim J, Cho Y, Chung S, Lee J, Sohn K . A 9-month-old phosphaturic mesenchymal tumor mimicking the intractable rickets. J Pediatr Orthop B. 2009; 19(1):127-32. DOI: 10.1097/BPB.0b013e32832f59cb. View

Ovejero D, El-Maouche D, Brillante B, Khosravi A, Gafni R, Collins M . Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy. J Bone Miner Res. 2017; 32(8):1667-1671. DOI: 10.1002/jbmr.3162. View

Beygi S, Denio A, Sharma T . The Foot That Broke Both Hips: A Case Report and Literature Review of Tumor-Induced Osteomalacia. Case Rep Rheumatol. 2017; 2017:3191673. PMC: 5618748. DOI: 10.1155/2017/3191673. View

Yin Z, Du J, Yu F, Xia W . Tumor-induced osteomalacia. Osteoporos Sarcopenia. 2019; 4(4):119-127. PMC: 6372818. DOI: 10.1016/j.afos.2018.12.001. View

Hughes M, Brumbaugh P, Hussler M, Wergedal J, Baylink D . Regulation of serum 1alpha,25-dihydroxyvitamin D3 by calcium and phosphate in the rat. Science. 1975; 190(4214):578-80. DOI: 10.1126/science.1188357. View

Ishii A, Imanishi Y, Kobayashi K, Hashimoto J, Ueda T, Miyauchi A . The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels. Calcif Tissue Int. 2010; 86(6):455-62. DOI: 10.1007/s00223-010-9369-9. View

Gonzalez-Lamuno D . Hypophosphataemic Rickets: Diagnosis Algorithm-How Not to Make a Mistake. Adv Ther. 2020; 37(Suppl 2):95-104. DOI: 10.1007/s12325-019-01184-1. View

Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K . Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444(7120):770-4. DOI: 10.1038/nature05315. View

Kim D, Sung D, Min Y . Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. J Bone Miner Metab. 2012; 31(2):240-6. DOI: 10.1007/s00774-012-0384-y. View

10.

Seufert J, Ebert K, Muller J, Eulert J, Hendrich C, Werner E . Octreotide therapy for tumor-induced osteomalacia. N Engl J Med. 2002; 345(26):1883-8. DOI: 10.1056/NEJMoa010839. View

11.

Sommer S, Berndt T, Craig T, Kumar R . The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol. 2007; 103(3-5):497-503. DOI: 10.1016/j.jsbmb.2006.11.010. View

12.

Sabbagh Y, Giral H, Caldas Y, Levi M, Schiavi S . Intestinal phosphate transport. Adv Chronic Kidney Dis. 2011; 18(2):85-90. PMC: 3071860. DOI: 10.1053/j.ackd.2010.11.004. View

13.

Cundy T, Que L, Hassan I, Hughes L . Bisphosphonate-Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome. JBMR Plus. 2020; 4(8):e10374. PMC: 7422711. DOI: 10.1002/jbm4.10374. View

14.

Reubi J, Waser B, Laissue J, Gebbers J . Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res. 1996; 56(8):1922-31. View

15.

Hazzazi M, Alzeer I, Tamimi W, Atawi M, Alwan I . Clinical presentation and etiology of osteomalacia/rickets in adolescents. Saudi J Kidney Dis Transpl. 2013; 24(5):938-41. DOI: 10.4103/1319-2442.118087. View

16.

Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella S . Tumour-induced osteomalacia. Nat Rev Dis Primers. 2017; 3:17044. DOI: 10.1038/nrdp.2017.44. View

17.

Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T . Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87(11):4957-60. DOI: 10.1210/jc.2002-021105. View

18.

Bergwitz C, Miyamoto K . Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy. Pflugers Arch. 2018; 471(1):149-163. DOI: 10.1007/s00424-018-2184-2. View

19.

. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26(3):345-8. DOI: 10.1038/81664. View

20.

Goretti Penido M, Alon U . Phosphate homeostasis and its role in bone health. Pediatr Nephrol. 2012; 27(11):2039-2048. PMC: 3461213. DOI: 10.1007/s00467-012-2175-z. View